Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection

Immunology. 2016 Jun;148(2):160-73. doi: 10.1111/imm.12594. Epub 2016 Mar 30.

Abstract

Influenza vaccination does not provide 100% protection from infection, partly due to antigenic drift of the haemagglutinin (HA) protein. Low serum antibody titres increase the risk of infection. To determine whether there were additional correlates of risk, we examined the relationship between human serum immunity and antigenic variation in seasonal H3N2 influenza viruses. Seasonal H3N2 vaccine strains grown in the presence of heterogeneous human or mono-specific ferret antisera selected variants with mutations in the HA antigenic sites. Surprisingly, circulating strains infecting human subjects in the same seasons displayed mutations in the same positions, although only in one case did the change correspond to the same amino acid. Serum antibody titres were lower against both the in vitro selected and clinical isolates compared with the vaccine strains, suggesting that the mutations are relevant to vaccine failure. Antibody titres were also significantly lower in sera from infected subjects than in non-infected subjects, suggesting relatively poor responses to vaccination in the infected subjects. Collectively, the data suggest that risk from influenza infection is a result of poor response to vaccination, as well as encounter with drifted seasonal influenza virus antigenic variants. The results also show that directed selection under human immune pressure could reveal antigenic variants relevant to real-world drifted viruses, helping in annual vaccine re-formulation.

Keywords: antigenic drift; circulating strains; haemagglutinin; human influenza virus; influenza virus vaccination; influenza-specific antibodies; vaccine strain.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Animals
  • Antibodies, Viral / blood
  • Antigenic Variation
  • Cell Line
  • Child, Preschool
  • Cohort Studies
  • Ferrets
  • Hemagglutinin Glycoproteins, Influenza Virus / genetics*
  • Hemagglutinin Glycoproteins, Influenza Virus / immunology
  • Humans
  • Immunity, Humoral*
  • Infant
  • Influenza A Virus, H1N1 Subtype / immunology
  • Influenza A Virus, H3N2 Subtype / genetics*
  • Influenza A Virus, H3N2 Subtype / immunology
  • Influenza Vaccines / immunology*
  • Influenza, Human / immunology*
  • Mutagenesis, Site-Directed
  • Prospective Studies
  • Seasons
  • Treatment Outcome
  • Vaccination

Substances

  • Antibodies, Viral
  • Hemagglutinin Glycoproteins, Influenza Virus
  • Influenza Vaccines

Associated data

  • GENBANK/GQ293081.1
  • GENBANK/KC306165.1
  • GENBANK/KR611819
  • GENBANK/KR611820
  • GENBANK/KR611821
  • GENBANK/KR611822
  • GENBANK/KR611823
  • GENBANK/KR611824
  • GENBANK/KR611825
  • GENBANK/KR611826-28
  • GENBANK/KR611829
  • GENBANK/KR611830-35
  • GENBANK/KR611836
  • GENBANK/KR611837
  • GENBANK/KR611838
  • GENBANK/KR611839-41
  • GENBANK/KR611842
  • GENBANK/KR611843
  • GENBANK/KR611844
  • GENBANK/KR611845
  • GENBANK/KR611846
  • GENBANK/KR611847
  • GENBANK/KR611848-52
  • GENBANK/KR861153
  • GENBANK/KR869978
  • GENBANK/KR869979